BUZZ-<a href="https://laohu8.com/S/BMEA">Biomea Fusion</a> rises as diabetes drug shows promise** Shares of drug developer Biomea Fusion BMEA.O rise 3.4% to $1.23 premarket
** Co says experimental drug, icovamenib, helped patients with severe type 2 diabetes maintain better blood sugar control nine months after treatment
** Study presented at World Congress on Insulin Resistance in Los Angeles, co says
** BMEA says drug aims to restore insulin-producing cells; tested in adults who failed up to three standard therapies
** No serious side effects reported; further trials planned with GLP-1 users later this year, says co
** As of last close, stock down ~69% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.